Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Budget Reductions Target FDA Field Operations

This article was originally published in The Tan Sheet

Executive Summary

President Obama’s fiscal 2016 budget request includes cuts to “low priority” enforcement, surveillance and other activities in the FDA human drugs and biologics programs, but still increases drug and biologics program budgets overall.

You may also be interested in...



Priority Review Vouchers Could Be Used Frequently Next Year

FDA requests enough pediatric rare disease priority review voucher user fees to fund three redemptions in fiscal year 2016.

FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections

CDER’s Woodcock says the new database will drive risk-based inspection decisions.

FDA Could Release GMP Data To Prod Manufacturing Improvements

Batch failure and other measures commonly tracked by manufacturers could be aggregated into an industry-wide index that FDA would use to help make risk-based inspection decisions.

Related Content

Topics

UsernamePublicRestriction

Register

PS107497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel